Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Want to cut your energy bills? Here’s how five experts are doing it 
WALTHAM, Mass., May 30, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017 at 11:00 a.m. Eastern Time.
The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
